Reviewed by Peptide Treatments Medical Advisory Board (Medical Advisory Board)
Cerebrolysin: Evidence Summary
Evidence summary for Cerebrolysin across studied indications. Each indication is graded using our evidence tier system based on the quality and quantity of available clinical data.
Back to Cerebrolysin overview| Indication | Evidence Tier | Trial Count | Summary |
|---|---|---|---|
| Stroke recovery | Tier B | 6 | European and Asian trials show improved neurological outcomes post-stroke |
| Alzheimer's disease | Tier C | 4 | Moderate improvements in cognitive function scales; mixed results across trials |
| Traumatic brain injury | Tier C | 3 | Accelerated recovery in moderate TBI; larger confirmatory trials needed |